Cogent Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cogent Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($80.93M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($73.53M) | Aug 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($73.53M) | Nov 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($71.99M) | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($71.99M) | Nov 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($71.99M) | Aug 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($70.63M) | Nov 7, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($58.95M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($58.95M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($58.35M) | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($58.35M) | Nov 7, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($58.35M) | Aug 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($55.38M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($44.08M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($44.08M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($38.59M) | May 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($38.59M) | Aug 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($38.59M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($35.06M) | Nov 7, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($34.93M) | Nov 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($83.36M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($75.58M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($74.93M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($75.41M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($64.39M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($62.40M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($59.58M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($47.09M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($43.24M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($36.82M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($35.86M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($31.42M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($19.82M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($17.29M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($12.80M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($57.20M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.40M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($6.14M) | May 12, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($12.04M) | Nov 9, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($10.54M) | Aug 11, 2020 |